Alkermes to Participate in Upcoming Investor Conferences
Alkermes plc (Nasdaq: ALKS) has announced its participation in two major investor conferences in December 2024. The company will present at the 7th Annual Evercore ISI HealthCONx Conference on December 3 at 10:25 a.m. ET and the Piper Sandler 36th Annual Healthcare Conference on December 4 at 4:00 p.m. ET.
The presentations will be accessible via live webcasts on the company's website under the Investors tab and will remain archived for 14 days. Alkermes is a global biopharmaceutical company focused on neuroscience, with commercial products for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company maintains operations in Ireland, Massachusetts, and Ohio.
Alkermes plc (Nasdaq: ALKS) ha annunciato la sua partecipazione a due importanti conferenze per investitori a dicembre 2024. L'azienda presenterà alla 7ª Conferenza Annuale Evercore ISI HealthCONx il 3 dicembre alle 10:25 a.m. ET e alla 36ª Conferenza Annuale sulla Salute di Piper Sandler il 4 dicembre alle 4:00 p.m. ET.
Le presentazioni saranno accessibili tramite webcast in diretta sul sito web dell'azienda sotto la sezione Investitori e rimarranno archiviate per 14 giorni. Alkermes è una società biofarmaceutica globale focalizzata sulle neuroscienze, con prodotti commerciali per la dipendenza da alcol, la dipendenza da oppioidi, la schizofrenia e il disturbo bipolare I. L'azienda ha operazioni in Irlanda, Massachusetts e Ohio.
Alkermes plc (Nasdaq: ALKS) ha anunciado su participación en dos importantes conferencias para inversores en diciembre de 2024. La compañía presentará en la 7ª Conferencia Anual Evercore ISI HealthCONx el 3 de diciembre a las 10:25 a.m. ET y en la 36ª Conferencia Anual de Salud de Piper Sandler el 4 de diciembre a las 4:00 p.m. ET.
Las presentaciones estarán disponibles a través de transmisiones web en vivo en el sitio web de la compañía bajo la pestaña de Inversores y permanecerán archivadas durante 14 días. Alkermes es una empresa biofarmaéutica global centrada en neurociencias, con productos comerciales para la dependencia del alcohol, la dependencia de opioides, la esquizofrenia y el trastorno bipolar I. La compañía tiene operaciones en Irlanda, Massachusetts y Ohio.
Alkermes plc (Nasdaq: ALKS)는 2024년 12월 두 개의 주요 투자자 회의에 참여한다고 발표했습니다. 회사는 12월 3일 오전 10시 25분 ET에 제7회 Evercore ISI HealthCONx 회의에서 발표하고, 12월 4일 오후 4시 ET에 Piper Sandler 제36회 건강 회의에서 발표할 예정입니다.
프레젠테이션은 회사 웹사이트의 투자자 탭에서 실시간 웹캐스트를 통해 액세스 가능하며, 14일 동안 아카이브됩니다. Alkermes는 알코올 의존증, 오피오이드 의존증, 조현병 및 양극성 장애 I에 대한 상용 제품을 보유한 신경과학에 중점을 둔 글로벌 바이오 제약 회사입니다. 이 회사는 아일랜드, 매사추세츠 및 오하이오에서 운영되고 있습니다.
Alkermes plc (Nasdaq: ALKS) a annoncé sa participation à deux grandes conférences d'investisseurs en décembre 2024. La société présentera à la 7ᵉ Conférence Annuelle Evercore ISI HealthCONx le 3 décembre à 10h25 ET et à la 36ᵉ Conférence Annuelle sur la Santé de Piper Sandler le 4 décembre à 16h00 ET.
Les présentations seront accessibles via des webinaires en direct sur le site de la société sous l'onglet Investisseurs et resteront archivées pendant 14 jours. Alkermes est une société biopharmaceutique mondiale axée sur les neurosciences, avec des produits commerciaux pour la dépendance à l'alcool, la dépendance aux opiacés, la schizophrénie et le trouble bipolaire de type I. L'entreprise exerce ses activités en Irlande, dans le Massachusetts et dans l'Ohio.
Alkermes plc (Nasdaq: ALKS) hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im Dezember 2024 bekannt gegeben. Das Unternehmen wird am 3. Dezember um 10:25 Uhr ET auf der 7. Jahrestagung der Evercore ISI HealthCONx präsentieren und am 4. Dezember um 16:00 Uhr ET auf der 36. Jahrestagung der Piper Sandler Healthcare Conference.
Die Präsentationen werden über Live-Webcasts auf der Website des Unternehmens unter dem Reiter Investoren zugänglich sein und 14 Tage lang archiviert bleiben. Alkermes ist ein globales biopharmazeutisches Unternehmen, das sich auf Neurowissenschaften spezialisiert hat und kommerzielle Produkte für Alkoholabhängigkeit, Opioidabhängigkeit, Schizophrenie und bipolare Störung Typ I anbietet. Das Unternehmen ist in Irland, Massachusetts und Ohio tätig.
- None.
- None.
7th Annual Evercore ISI HealthCONx Conference
Date/Time: Tuesday, Dec. 3, 2024 at 10:25 a.m. ET (3:25 p.m. GMT)
Piper Sandler 36th Annual Healthcare Conference
Date/Time: Wednesday, Dec. 4, 2024 at 4:00 p.m. ET (9:00 p.m. GMT)
The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in
Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402
View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-participate-in-upcoming-investor-conferences-302315492.html
SOURCE Alkermes plc
FAQ
When is Alkermes (ALKS) presenting at the Evercore ISI HealthCONx Conference in December 2024?
What time is Alkermes (ALKS) presenting at the Piper Sandler Healthcare Conference in December 2024?
How long will Alkermes (ALKS) investor conference webcasts be available for viewing?
What therapeutic areas does Alkermes (ALKS) focus on as of 2024?
